Prenetics Global Limited

NasdaqGM:PRE Stock Report

Market Cap: US$55.4m

Prenetics Global Past Earnings Performance

Past criteria checks 0/6

Prenetics Global's earnings have been declining at an average annual rate of -22.3%, while the Healthcare industry saw earnings growing at 7% annually. Revenues have been growing at an average rate of 7.7% per year.

Key information

-22.3%

Earnings growth rate

3.4%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate7.7%
Return on equity-26.8%
Net Margin-250.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues

Apr 08
Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues

Prenetics Global Limited (NASDAQ:PRE) Held Back By Insufficient Growth Even After Shares Climb 30%

Jan 07
Prenetics Global Limited (NASDAQ:PRE) Held Back By Insufficient Growth Even After Shares Climb 30%

Prenetics Global GAAP EPS of -$2.91, revenue of $51.72M

Sep 09

Revenue & Expenses Breakdown
Beta

How Prenetics Global makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:PRE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2322-545012
30 Sep 23280-1818421
30 Jun 23279-239818
31 Mar 23201-16818415
31 Dec 22276-19019916
30 Sep 22288-27823117
30 Jun 22283-34323416
31 Mar 22310-20912913
31 Dec 21276-17410611
30 Sep 21238-94676
30 Jun 21190-4435
31 Mar 211191294
31 Dec 2065-2233
31 Dec 199-20183

Quality Earnings: PRE is currently unprofitable.

Growing Profit Margin: PRE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PRE is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.

Accelerating Growth: Unable to compare PRE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRE is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.2%).


Return on Equity

High ROE: PRE has a negative Return on Equity (-26.84%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.